References
- Pedersen MB , ZhouX, LarsenEKet al. Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation. J. Immunol. 184, 1931–1945 (2010).
- Kedmi R , Ben-ArieN, PeerD. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials31, 6867–6875 (2010).
- Peer D . Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. Adv. Drug Deliv. Rev.64, 1738–1748 (2012).
- Landesman-Milo D , PeerD. Altering the immune response with lipid-based nanoparticles. J. Control. Release161, 600–608 (2012).
- Peer D . A daunting task: manipulating leukocyte function with RNAi. Immunol. Rev.253, 185–197 (2013).
- Moyano DF , GoldsmithM, SolfiellDJet al. Nanoparticle hydrophobicity dictates immune response. J. Am. Chem. Soc. 134, 3965–3967 (2012).
- Ebbesen MF , WhiteheadB, Ballarin-GonzalezB, KingshottP, HowardKA. Surface analysis of PEGylated nano-shields on nanoparticles installed by hydrophobic anchors. Pharm. Res. doi: 10.1007/s11095-013-1018-3 (2013) (Epub ahead of print).
- Filipe V , HaweA, JiskootW. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm. Res.27, 796–810 (2010).
- Howard KA , RahbekUL, LiuXet al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14, 476–484 (2006).
- Liu X , HowardKA, DongMet al. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 28, 1280–1288 (2007).
- Howard KA , DongM, OupickyDet al. Nanocarrier stimuli-activated gene delivery. Small 3, 54–57 (2007).
- Rahbek UL , HowardKA, OupickyDet al. Intracellular siRNA and precursor miRNA trafficking using bioresponsive copolypeptides. J. Gene Med. 10, 81–93 (2008).
- Kirchhausen T , BollW, van Oijen A, Ehrlich M. Single-molecule live-cell imaging of clathrin-based endocytosis. Biochem. Soc. Symp.72, 71–76 (2005).
- Akinc A , QuerbesW, DeSet al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357–1364 (2010).
- Macia E , EhrlichM, MassolR, BoucrotE, BrunnerC, KirchhausenT. Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell10, 839–850 (2006).
- Newton AJ , KirchhausenT, MurthyVN. Inhibition of dynamin completely blocks compensatory synaptic vesicle endocytosis. Proc. Natl Acad. Sci. USA103, 17955–17960 (2006).
- Larsen EK , NielsenT, WittenbornTet al. Size-dependent accumulation of PEGylated silane-coated magnetic iron oxide nanoparticles in murine tumors. ACS Nano 3, 1947–1951 (2009).
- Nawroth I , AlsnerJ, DeleuranBWet al. Peritoneal macrophages mediated delivery of chitosan/siRNA nanoparticle to the lesion site in a murine radiation-induced fibrosis model. Acta Oncol. doi: 10.3109/0284186X.2012.726373 (2012) (Epub ahead of print).
- Szebeni J , MoghimiSM. Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions. J. Liposome Res.19, 85–90 (2009).
- Andersen AJ , HashemiSH, AndresenTL, HunterAC, MoghimiSM. Complement: alive and kicking nanomedicines. J. Biomed. Nanotechnol.5, 364–372 (2009).
- Peer D , ParkEJ, MorishitaY, CarmanCV, ShimaokaM. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science319, 627–630 (2008).
- Akinc A , GoldbergM, QinJet al. Development of lipidoid–siRNA formulations for systemic delivery to the liver. Mol. Ther. 17(5), 872–879 (2009).